Proton pump inhibitor use is not associated with cardiac arrhythmia in critically ill patients

Journal of Clinical Pharmacology

Volumn 55, Issue 7, 2015, Pages 774-779

  Chen, Kenneth P ^a   Lee, Joon ^b,c   Mark, Roger G ^c   Feng, Mengling ^c   Celi, Leo A ^a,c   Malley, Brian E ^d   Danziger, John ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b UNIVERSITY OF WATERLOO   (Canada)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d OAKLAND UNIVERSITY WILLIAM BEAUMONT SCHOOL OF MEDICINE   (United States)

Author keywords

arrhythmia; hypomagnesemia; proton pump inhibitor

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR; MAGNESIUM;

AGED; ARTICLE; ATRIAL BRADYCARDIA; ATRIAL FIBRILLATION; ATRIOVENTRICULAR JUNCTION ARRHYTHMIA; BRADYCARDIA; CARDIOVASCULAR RISK; COHORT ANALYSIS; CRITICALLY ILL PATIENT; DISEASE ASSOCIATION; DIURETIC THERAPY; DRUG EXPOSURE; ELECTROCARDIOGRAM; FEMALE; HEART ARRHYTHMIA; HEART ATRIUM ARRHYTHMIA; HEART ATRIUM FLUTTER; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HIGH RISK PATIENT; HOSPITAL ADMISSION; HUMAN; HYPOMAGNESEMIA; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; RETROSPECTIVE STUDY; RISK FACTOR; SUPRAVENTRICULAR BRADYCARDIA; SUPRAVENTRICULAR PREMATURE BEAT; SUPRAVENTRICULAR TACHYCARDIA; TREATMENT OUTCOME; ARRHYTHMIAS, CARDIAC; BLOOD; CHEMICALLY INDUCED; COMPARATIVE STUDY; CRITICAL ILLNESS; ELECTROCARDIOGRAPHY; MIDDLE AGED; RISK; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ARRHYTHMIAS, CARDIAC; CRITICAL ILLNESS; DIURETICS; ELECTROCARDIOGRAPHY; FEMALE; HISTAMINE H2 ANTAGONISTS; HUMANS; MAGNESIUM; MALE; MIDDLE AGED; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES; RISK;

EID: 84930622922     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.479     Document Type: Article

References (32)

1. Cundy T., Dissanayake A,. Severe hypomagnesaemia in long-term users of proton-pump inhibitors. Clin Endocrinol (Oxf). 2008; 69 (2): 338-341.
2. Shabajee N, Lamb EJ, Sturgess I, Sumathipala RW,. Omeprazole and refractory hypomagnesaemia. BMJ. 2008; 337: a425.
3. Broeren MA, Geerdink EA, Vader HL, van den Wall Bake AW,. Hypomagnesemia induced by several proton-pump inhibitors. Ann Intern Med. 2009; 151 (10): 755-756.
4. Kuipers MT, Thang HD, Arntzenius AB,. Hypomagnesaemia due to use of proton pump inhibitors-a review. Neth J Med. 2009; 67 (5): 169-172.
5. Hoorn EJ, van der Hoek J, de Man RA, Kuipers EJ, Bolwerk C, Zietse R,. A case series of proton pump inhibitor-induced hypomagnesemia. Am J Kidney Dis. 2010; 56 (1): 112-116.
6. Mackay JD, Bladon PT,. Hypomagnesaemia due to proton-pump inhibitor therapy: a clinical case series. Qjm. 2010; 103 (6): 387-395.
7. Regolisti G, Cabassi A, Parenti E, Maggiore U, Fiaccadori E,. Severe hypomagnesemia during long-term treatment with a proton pump inhibitor. Am J Kidney Dis. 2010; 56 (1): 168-174.
8. Negri AL, Valle EE,. Hypomagnesaemia/hypokalemia associated with the use of esomeprazole. Curr Drug Saf. 2011; 6 (3): 204-206.
9. Quasdorff M, Mertens J, Dinter J, Steffen HM,. Recurrent hypomagnesemia with proton-pump inhibitor rechallenge. Ann Intern Med. 2011; 155 (6): 405-407.
10. Faulhaber GA, Ascoli BM, Lubini A, et al., Serum magnesium and proton-pump inhibitors use: a cross-sectional study. Rev Assoc Med Bras. 2013; 59 (3): 276-279.
11. Koulouridis I, Alfavez M, Tighiouart H, et al., Out-of-hospital use of proton pump inhibitors and hypomagnesemia at hospital admission: a nested case-control study. Am J Kidney Dis,. 2013; 62 (4): 730-737.
12. Van Ende C, Van Laecke S, Marechal C, et al., Proton-pump inhibitors do not influence serum magnesium levels in renal transplant recipients. J Nephrol. 2014.
13. Danziger J, William JH, Scott DJ, et al., Proton-pump inhibitor use is associated with low serum magnesium concentrations. Kidney Int. 2013; 83 (4): 692-699.
14. Zipursky J, Macdonald EM, Hollands S, et al., Proton pump inhibitors and hospitalization with hypomagnesemia: a population-based case-control study. PLoS Med. 2014; 11 (9): e1001736.
15. William JH, Nelson R, Hayman N, Mukamal KJ, Danziger J,. Proton-pump inhibitor use is associated with lower urinary magnesium excretion. Nephrology (Carlton). 2014; 19 (12): 798-801.
16. Kolte D, Vijayaraghavan K, Khera S, Sica DA, Frishman WH,. Role of magnesium in cardiovascular diseases. Cardiol Rev. 2014; 22 (4): 182-192.
17. El-Charabaty E, Saifan C, Abdallah M, et al., Effects of proton pump inhibitors and electrolyte disturbances on arrhythmias. Int J Gen Med. 2013; 6: 515 -518.
18. Saeed M, Villaroel M, Reisner AT, et al., Multiparameter Intelligent Monitoring in Intensive Care II: a public-access intensive care unit database. Crit Care Med. 2011; 39 (5): 952-960.
19. Swaminathan K, Wilson J,. Elusive cause of hypomagnesaemia. BMJ. 2011; 343: d5087.
20. Iseri LT, Allen BJ, Ginkel ML, Brodsky MA,. Ionic biology and ionic medicine in cardiac arrhythmias with particular reference to magnesium. Am Heart J. 1992; 123 (5): 1404 -1409.
21. Rasmussen HS, Thomsen PE,. The electrophysiological effects of intravenous magnesium on human sinus node, atrioventricular node, atrium, and ventricle. Clin Cardiol. 1989; 12 (2): 85-90.
22. DiCarlo Jr LA, Morady F, de Buitleir M, Krol RB, Schurig L, Annesley TM, et al., Effects of magnesium sulfate on cardiac conduction and refractoriness in humans. J Am Coll Cardiol. 1986; 7 (6): 1356-1362.
23. Viskin S, Belhassen B, Sheps D, Laniado S, et al., Clinical and electrophysiologic effects of magnesium sulfate on paroxysmal supraventricular tachycardia and comparison with adenosine triphosphate. Am J Cardiol. 1992; 70 (9): 879-885.
24. Christiansen EH, Frost L, Andreasen F, Mortensen P, Thomsen PE, Pedersen AK,. Dose-related cardiac electrophysiological effects of intravenous magnesium. A double-blind placebo-controlled dose-response study in patients with paroxysmal supraventricular tachycardia. Europace. 2000; 2 (4): 320-326.
25. Bailie DS, Inoue H, Kaseda S, Ben-David J, Zipes DP,. Magnesium suppression of early afterdepolarizations and ventricular tachyarrhythmias induced by cesium in dogs. Circulation. 1988; 77 (6): 1395-1402.
26. Kaseda S, Gilmour Jr RF, Zipes DP,. Depressant effect of magnesium on early afterdepolarizations and triggered activity induced by cesium, quinidine, and 4- aminopyridine in canine cardiac Purkinje fibers. Am Heart J. 1989; 118 (3): 458-466.
27. Satoh Y, Sugiyama A, Tamura K, Hashimoto K,. Effect of magnesium sulfate on the haloperidol-induced QT prolongation assessed in the canine in vivo model under the monitoring of monophasic action potential. Jpn Circ J. 2000; 64 (6): 445-451.
28. Moskowitz A, Lee J, Donnino MW, Mark R, Celi LA, Danziger J,. The association between admission magnesium concentrations and lactic acidosis in critical illness. J Intensive Care Med. 2014.
29. Zellerhoff S, Lenze F, Eckardt L,. Prophylactic proton pump inhibition after atrial fibrillation ablation: is there any evidence? Europace. 2011; 13 (9): 1219-1221.
30. Lin K, Chen X, Zhang L, Wang Y, Shan Z,. Proton pump inhibitors as also inhibitors of atrial fibrillation. Eur J Pharmacol. 2013; 718 (1-3): 435-440.
31. Schulz-Geske S, Erdmann K, Wong RJ, Stevenson DK, Schröder H, Grosser N,. Molecular mechanism and functional consequences of lansoprazole-mediated heme oxygenase-1 induction. World J Gastroenterol. 2009; 15 (35): 4392-4401.
32. De Jonge PJ, Siersema PD, Van Brada SG, et al., Proton pump inhibitor therapy in gastro-oesophageal reflux disease decreases the oesophageal immune response but does not reduce the formation of DNA adducts. Aliment Pharmacol Ther. 2008; 28 (1): 127-136.